A two-part phase 2 randomized study of dalantercept and axitinib versus placebo plus axitinib in advanced renal cell carcinoma: Results from the part 1 dose escalation cohorts.
Michael B. Atkins
Consultant or Advisory Role - Acceleron Pharma
Martin Henner Voss
Honoraria - Novartis
Research Funding - Bristol-Myers Squibb; Pfizer
Elizabeth R. Plimack
No relevant relationships to disclose
Brian I. Rini
Consultant or Advisory Role - Bayer; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Pfizer
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; immatics; Merck; Pfizer; Roche
Robert Alter
Consultant or Advisory Role - Algeta; Astellas/Medivation; Bayer; Bristol-Myers Squibb; Dendreon; Janssen
Honoraria - Amgen; Astellas/Medivation; Bayer/Algeta; Dendreon; Pfizer; Teva
Nancy Ann Dawson
Consultant or Advisory Role - Pfizer
J. Thaddeus Beck
No relevant relationships to disclose
Rupal Satish Bhatt
Consultant or Advisory Role - Acceleron Pharma
Research Funding - Acceleron Pharma
Kristen M. Pappas
Employment or Leadership Position - Acceleron Pharma
Dawn Wilson
Employment or Leadership Position - Acceleron Pharma
Stock Ownership - Acceleron Pharma
Ty McClure
Consultant or Advisory Role - Acceleron Pharma
Stock Ownership - Acceleron Pharma
Ravi Kumar
Employment or Leadership Position - Acceleron Pharma
Stock Ownership - Acceleron Pharma
Kenneth M. Attie
Employment or Leadership Position - Acceleron Pharma
Stock Ownership - Acceleron Pharma
Matthew L. Sherman
Employment or Leadership Position - Acceleron Pharma
Stock Ownership - Acceleron Pharma
Shuchi Sumant Pandya
Employment or Leadership Position - Acceleron Pharma
Stock Ownership - Acceleron Pharma